A5053459736- Malaria Research and Control
- Drug Transport and Resistance Mechanisms
- bioluminescence and chemiluminescence research
- Trypanosoma species research and implications
- Traditional and Medicinal Uses of Annonaceae
- CRISPR and Genetic Engineering
- Animal Genetics and Reproduction
University of Washington
2025
National Institute of Allergy and Infectious Diseases
2018-2020
National Institutes of Health
2018-2020
Abstract The malaria parasite has a complex lifecycle involving various host cell environments in both human and mosquito hosts. must tightly regulate gene expression at each stage order to adapt its current environment while continuing development. However, it is challenging study function regulation of essential genes across the parasite’s multi-host lifecycle. Thus, we adapted recently developed single-plasmid dimerizable Cre recombinase system for rapamycin-controllable Cas9, allowing...
Significance The mitochondrial electron transport chain (ETC) of Plasmodium falciparum malaria parasites contains targets for antimalarial drug development including cytochrome B (PfCytB) and NADH dehydrogenase 2 (PfNDH2). Atovaquone (ATQ), a widely used drug, is hydroxynaphthoquinone inhibitor PfCytB; substituted quinolone compounds (CK-2-68 RYL-552) have also been developed as putative inhibitors PfNDH2. Unexpectedly, our experiments yielded mutations PfCytB, not PfNDH2, in selected with...
Lumefantrine and mefloquine are used worldwide in artemisinin-based combination therapy (ACT) of malaria. Better understanding drug susceptibility resistance is needed can be obtained from studies genetic crosses. Drug response phenotypes a cross between Plasmodium falciparum lines 803 (Cambodia) GB4 (Ghana) were as half-maximal effective concentrations (EC50s) days to recovery (DTR) after 24 h exposure 500 nM lumefantrine. EC50s mefloquine, halofantrine, chloroquine, dihydroartemisinin also...